BPMed Cosmetic

http://bpmedcosmetic.tradekorea.com

BPMed Cosmetic Co,. Ltd.  is the manufacturer of skin care cosmetic using  “Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40”, which has been registered on ICID (International Cosmetic Ingredient Dictionary) first in the world as a botulinum toxin, material of Botox, derivative cosmetic ingredient. (国际化妆品原料回家的真正的肉毒杆菌成分的由来).   The company was established in Jan. 2016 after complete developing main ingredient and preparing everything about first product.   Trademark registered in 8 countries with “BoLCA+”, meaning of “Botulinum Light Chain type A”. Starting exclusive contract with the Ukraine and nearby five countries, it’s under introducing products and supplying agreements for domestic and foreign companies with favorable.   BPMed Cosmetic is the only company who has Botulinum derivative cosmetic ingredient for now.  “Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40” is the cosmetic ingredient.   Existing botulinum toxin (Botox) injections are only for medical and pharmaceutical, so not allowed to use in cosmetic products. And there’s no any efficacy when apply on the skin since its molecular weight is too big for penetrating skin.   As a result of working with the company who has been developing botulinum toxin injection as well as secured botulinum toxin and the company who has been developing technology of macromolecule penetrating to target cell, the new recombinant protein cosmetic ingredient has born.  The structure is binding of botulinum light chain and MTD (Macromolecule Transduction Domain) protein sequence. These things was just a dream of not only BPMed Cosmetic CEO Yoon KiYoung, the early member of Meditox Co,. Ltd., company launched the botulinum toxin injection first in Korea, but also world botulinum industry. it was attempted by chance while he was helping fourth Korean botulinum company and waiting the MTD technology to be advanced enough, but the dream has been realized.   At this moment, Botulinum dinosaur Allegan is attempting topical botulinum by taking over the company Anterios of 90 billion USD on Jan. 2016, and leading pharmaceutical company Revance Therapeutics failed to get validity acquisition on phase 3 on Jun. 2016. We are introducing proud “Made In Korea” of the beauty power Korea.   Up to now there are so many cosmetic products has been advertised as “Botox Cosmetic”. However, there was no product containing ingredient related to Botox or Botulinum.   “BoLCA+” has the meaning of the first botulinum-derivative cosmetic ingredient. It can be proven by including “Clostridium Botulinum” on its INCI (International Nomenclature Cosmetic Ingredient) name, which has been given by PCPC (Personal Care Products Council, supervising ICID registration) and global cosmetic companies for classification of raw materials. And also if search ICID database by keyword “Botulinum”, there is only one result shown.   There was a lot of cosmetic ingredient showing great effect on cell experimental phase, but it’s extremely rare passing through enormous barrier epidermis, skin. There is second important meaning that our botulinum ingredient directly works on neuron cells in dermis by penetrating epidermis. It is commonly known the botulinum toxin injection is to muscle layer for wrinkle improvement by relaxation.  About 10 years ago, Korean doctors who has most advanced beauty technology launched treatment injecting 100~200 times diluted Botox to the facial dermis for skin improvement, not for muscular lines. This treatment is so called DermoToxin, SkinBotox, MicroBotox.  Our ingredient cannot reach to the muscle by penetrating fat layer under dermis. But we can show same efficacy of dermis injection treatment by safe and convenient way. And its efficacies include all the items you can expect from cosmetic products except sunscreen. These are already proven by dermis injection treatment, not our products.